((自动化翻译由路透提供，请见免责声明 ))
11月12日 - ** Mirum Pharmaceuticals 股价上涨5.7%至43.97美元
** 公司将 2024 年的营业额预期从之前的 3.1 亿至 3.2 亿美元上调至 3.3 亿至 3.35 亿美元。
** (link) 公布第三季度营业收入为 9,030 万美元，高于分析师预计的 8,200 万美元 - LSEG
** 公布第三季度每股亏损 30 美分，低于分析师预计的 45 美分 - LSEG
** 公司的肝病药物 Livmarli 第三季度实现营业收入 5910 万美元，高于分析师预计的 5000 万美元 - LSEG
** 覆盖 MIRM 的所有 11 家券商均将该股评为 "买入 "或更高；中位数 PT 为 65.50 美元 - LSEG
** 该股今年累计上涨约49%，包括盘中涨幅
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.